Serum determination of C-terminal telopeptide of type 1 collagen (CTx) is a sensitive bone resorption marker in renal osteodystrophy

Wittich, A.; Casco, C.; Oviedo, Alejandra; Zeni, Susana Noemí; Nadal, Miguel Angel; Mautalén, C.

doi:10.1016/s8756-3282(01)00529-4

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biochemical bone markers reflecting remodeling include resorption markers such as collagen cross-links, while alkaline phosphatase is an example of a marker of bone formation [ 3 , 8 ]. Among several bone turnover markers reported in the literature [ 9 , 10 ], collagen is the main extracellular protein in the body and forms more than 25% of bone by volume. Collagen also constitutes 65% of the total organic component of bone tissue and is thus a good marker to study bone health [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

A Label-Free Electronic Biosensor for Detection of Bone Turnover Markers

Yun

Bhattacharya

Watts

et al. 2009

Sensors

View full text Add to dashboard Cite

This paper describes the development of a biosensor based on label-free immunosensing for the detection of the C-terminal telopeptide bone turnover marker from type-1 collagen. A self-assembled monolayer (SAM) of dithiodipropionic acid was deposited on a gold electrode. Then streptavidin and biotinylated anti-human C-terminal telopeptide antibody were successively conjugated on the self-assembled monolayer. Electrochemical impedance measurements were made to characterize each step of the SAM/streptavidin/biotinylated antibody binding. Subsequently, electrochemical impedance was measured with different concentrations of C-teminal telopeptide. A detection limit of 50 ng/mL and a dynamic range up to 3 μg/mL were achieved. To our knowledge, this is the first attempt to develop a label-free immunosensor based on electrochemical impedance with DC bias for detection of bone-related degradation and rebuilding products. The electronic biosensor might eventually be used for quantitative point-of-care screening of bone health. It is hoped that analysis of bone turnover markers can indicate the beginning of bone diseases such as osteoarthritis and osteoporosis so that treatment might start early when it is most effective.

show abstract